GlassScriptPhysician profile
Steji Koshy
NPI 1982087946
$5,041.67
in general payments reported to CMS, 2019-2025
16 companies · $1,721 in 2025
The $1,721 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $507 · 2022: $657 · 2023: $882 · 2024: $1,275 · 2025: $1,721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,872 · Education: $5.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,872.35 |
| Education | $5.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,012.27 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $710.68 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $371.72 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $355.76 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $354.81 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $316.74 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $233.63 | 2023-2025 | Invega, Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $226.21 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $207.37 | 2024-2025 | Auvelity |
| Indivior INC. | $83.05 | 2023-2024 | Perseris |
| Braeburn INC. | $42.54 | 2025 | Brixadi |
| Sanofi Pasteur INC. | $37.24 | 2021-2022 | |
| Noven Therapeutics, LLC | $32.43 | 2024 | Xelstrym, Secuado |
| Corium, LLC | $25.86 | 2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $15.98 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $15.38 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steji Koshy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.